How to Get IVIG Covered by Insurance and Fight Denials

Getting IVIG (intravenous immunoglobulin) covered by insurance typically requires thorough documentation of medical necessity, a willingness to navigate prior authorization, and a readiness to appeal if the initial request is denied. The process can be frustrating: in one survey of families seeking IVIG for a neuroinflammatory condition, only 18% received insurance approval without filing an appeal.¹ IVIG is one of the most expensive recurring therapies in medicine, and insurers scrutinize requests heavily, but the appeals process does work for many patients when handled strategically.

Why IVIG Denials Are So Common

IVIG sits in an unusual spot in the insurance landscape. It has FDA approval for roughly half a dozen conditions, but those approved indications account for only about half of all IVIG use.² The other half is prescribed off-label for conditions where clinical evidence supports its use but where formal FDA approval has never been sought. Off-label prescribing is legal and common in medicine, but it gives insurers an easy foothold for denial: if a therapy isn’t FDA-approved for your specific diagnosis, the insurer can argue it isn’t “medically necessary” under the plan’s terms.

Even for FDA-approved conditions, insurers impose significant restrictions. A review of U.S. health plan coverage policies for neuromuscular disease therapies found that 96% of covered therapies had restrictions beyond what the FDA label requires.³ These restrictions might include step therapy requirements (you have to try cheaper treatments first and fail them), specific lab result thresholds, or documentation that alternative treatments were considered. The average initial approval duration was six months, with reauthorization periods averaging ten months, meaning you may need to re-prove medical necessity repeatedly.³

The cost of IVIG itself is a major factor. A single infusion can run thousands of dollars, and many patients need treatments every few weeks indefinitely. Insurers know this is a long-term financial commitment, and their utilization management programs are designed to limit approvals to cases where the evidence is strongest. An analysis of over 2,500 immunoglobulin prior authorization requests found that while about 82% were ultimately authorized, only around 58% of the underlying diagnoses were classified as “supported” by the medical literature. Another third were “conditional,” meaning evidence existed but with caveats.⁴ Requests for FDA-approved indications were authorized at a higher rate, around 85%, compared to off-label uses.⁴

Building a Strong Prior Authorization Request

The prior authorization stage is where most of the battle is won or lost. Think of the prior authorization request not as a bureaucratic form but as a medical argument your physician is making to the insurer’s medical reviewer. The stronger the documentation upfront, the less likely you are to face a denial and the exhausting appeals process that follows.

Your physician’s letter of medical necessity is the centerpiece. It should do several things clearly:

Name the diagnosis precisely: Use the specific ICD-10 code and spell out the condition. Vague or overly broad diagnostic language invites denial.
Cite the evidence base: Reference published clinical guidelines, peer-reviewed studies, or expert consensus statements that support IVIG for your condition. If your diagnosis is FDA-approved for IVIG, say so explicitly. If it’s off-label, cite the strongest available evidence.
Document failed alternatives: If your insurer requires step therapy, list every treatment you’ve tried, how long you tried it, and why it didn’t work or why it’s contraindicated. Include dates, dosages, and objective measures of failure.
Include objective clinical data: Lab results (immunoglobulin levels, antibody titers, nerve conduction studies, muscle strength scores, or whatever is relevant to your condition) carry more weight than subjective symptom descriptions alone.
State the treatment plan: Specify the proposed dose, frequency, and duration. Insurers are more likely to approve a defined treatment plan than an open-ended one.

For conditions where IVIG is well established, such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), or immune thrombocytopenia, the prior authorization process tends to be more straightforward because clinical guidelines are well defined. For less common or off-label indications, the documentation burden shifts heavily to your physician. Ask your doctor whether they’ve submitted IVIG authorizations before and whether the practice has a staff member experienced in navigating these requests.

When the Denial Letter Arrives

A denial is not a final answer. It’s the start of a structured process that, by law, gives you the right to challenge the decision. The first thing to do is read the denial letter carefully. Insurers are required to state the specific reason for the denial. Common reasons include:

Not medically necessary: The insurer’s medical reviewer concluded the documentation didn’t demonstrate that IVIG is needed for your condition.
Experimental or investigational: The insurer considers IVIG unproven for your particular diagnosis, which is especially common for off-label uses.
Incomplete documentation: The request was missing required records, labs, or clinical notes.
Step therapy not completed: You haven’t tried the cheaper alternatives the plan requires first.
Dosing or frequency issues: The requested amount or schedule exceeds what the insurer’s guidelines allow.

The reason matters because it dictates your response strategy. A denial for incomplete documentation is the simplest to fix: gather the missing records and resubmit. A denial for medical necessity requires a more substantial appeal with additional clinical evidence. Knowing what the insurer specifically objected to lets you address the gap directly rather than broadly restating the case.

You typically have a limited window to file an appeal, often 30 to 180 days depending on the plan and state, so don’t delay. Note the deadline from the denial letter and work backward from it.

How to File an Effective Internal Appeal

Most insurance plans allow at least one level of internal appeal, and many allow two. The internal appeal goes to a different reviewer within the insurance company than the one who made the original denial decision. This matters because a fresh set of eyes and a stronger package of evidence can yield a different result.

The appeal letter should be written by your physician and should directly address the stated denial reason. If the denial said “not medically necessary,” the appeal should explain why IVIG is, in fact, necessary for you specifically. Reference clinical guidelines from professional medical societies, peer-reviewed literature, and your individual clinical trajectory. If you’ve deteriorated since the denial or if new test results strengthen the case, include those.

Peer-to-peer review is a tool available during the internal appeal process. Your physician can request a phone call with the insurance company’s medical director to discuss your case directly. These conversations can be productive because they allow the treating physician to explain clinical nuances that don’t translate well on paper. If your doctor is willing to do this, it’s worth requesting. Some denials get overturned at this stage without needing a formal written appeal.

Patient advocacy organizations for your specific condition often have template appeal letters, sample letters of medical necessity, and lists of supporting literature. Organizations focused on immunodeficiency, neuromuscular diseases, or autoimmune conditions have been navigating IVIG denials for years and can share what language and evidence has worked. Taking advantage of these resources can save you considerable time.

External Review and State-Level Protections

If your internal appeals are exhausted and the insurer still denies coverage, you have the right under the Affordable Care Act (for most private insurance plans) to request an independent external review. An external review is conducted by a third party that has no financial relationship with your insurer. The external reviewer examines your medical records, the insurer’s denial rationale, and the relevant clinical evidence, and makes a binding determination.

External review is a meaningful safeguard because it takes the decision out of the insurer’s hands entirely. The external reviewer is typically a physician with expertise in the relevant specialty. For conditions where the medical literature supports IVIG, even if it’s off-label, a knowledgeable external reviewer may reach a different conclusion than the insurer’s utilization management team.

State insurance departments also play a role. Patients can file complaints with their state’s insurance commissioner when they believe a denial was improper. A survey of state insurance commissioner offices found that 29% reported receiving complaints related to denial of care by managed care organizations.⁵ Most of these complaints were resolved without formal regulatory action, which suggests that the complaint process itself can prompt insurers to reconsider. Filing a complaint with the state insurance department doesn’t replace the appeal process, but it creates a paper trail and additional pressure.

For patients on Medicare or Medicaid, the appeal pathways differ from commercial insurance. Medicare has a structured five-level appeal process that can ultimately reach federal court. Medicaid appeals follow state-specific rules, and many states offer expedited fair hearings when ongoing treatment is at risk of interruption. If you’re on a government plan, contact your state’s health insurance assistance program (SHIP) for free guidance on how to navigate the specific appeals process.

The Difference Between FDA-Approved and Off-Label Uses

Understanding where your diagnosis falls on the spectrum of evidence matters for your strategy. FDA-approved indications for IVIG include primary immunodeficiency disorders, immune thrombocytopenia, CIDP, Kawasaki disease, multifocal motor neuropathy, and certain complications of bone marrow transplant. If your diagnosis is one of these, your authorization request rests on strong regulatory ground, and denial rates tend to be lower. Among the 2,500-plus prior authorization requests analyzed in one large review, requests for FDA-approved indications were authorized about 85% of the time.⁴

For off-label uses, the landscape is more complicated. Conditions like myasthenia gravis, Guillain-Barré syndrome, certain autoimmune encephalitides, and PANS/PANDAS have varying levels of published evidence supporting IVIG. Some have strong clinical trial data and professional society guidelines recommending IVIG; others rely on smaller studies and case series. The more robust the evidence you can present, the better your chances. Your physician should reference the specific studies and guidelines most relevant to your condition, ideally from the treating specialty’s professional society.

The PANS experience illustrates how dramatically diagnosis affects the timeline. In the survey of PANS families, among those receiving IVIG for a comorbid condition that already had established IVIG coverage (like an immunodeficiency), 38% began treatment within a month of the doctor’s order. Among those receiving IVIG for PANS alone, only 5% were treated within a month, and 14% waited nine months or longer before treatment began.¹ If you have a comorbid condition that independently qualifies for IVIG, making sure it’s documented prominently in the authorization request can expedite coverage.

Choosing the Infusion Setting Strategically

Where you receive IVIG can affect both cost and insurance willingness to cover it. IVIG can be administered in a hospital outpatient infusion center, a freestanding infusion suite, or at home with a specialty infusion nursing service. The cost to the insurer varies enormously across these settings, and some insurers are more willing to approve IVIG when the setting is less expensive.

Home infusion is worth discussing with your physician and insurer. A study comparing home versus outpatient hospital IVIG found that patients receiving infusions at home had significantly lower odds of emergency department visits and inpatient hospital stays compared to those treated in hospital outpatient settings.⁶ Some insurers actively prefer home infusion because the facility fees are lower than hospital-based settings, and the reduced hospitalization and emergency visits represent downstream savings. If your insurer has denied IVIG at a hospital outpatient center, ask whether they would cover it through a home infusion provider. Sometimes switching the site of care can break a coverage impasse.

That said, not every patient is a candidate for home infusion. If you’ve had infusion reactions in the past, if your first infusions need close monitoring, or if your medical situation is complex, your physician may recommend starting in a clinical setting and transitioning home after tolerance is established. The insurer should not be the one making this clinical judgment, but being flexible about setting when it’s medically appropriate gives you more room to negotiate.

Subcutaneous Immunoglobulin as an Alternative

Subcutaneous immunoglobulin (SCIG) delivers the same antibodies as IVIG but through a small needle placed under the skin instead of into a vein. The infusions are slower and more frequent, typically weekly rather than every three to four weeks, but they can be self-administered at home after training. For some insurance plans, SCIG is easier to get approved because it eliminates facility fees and nursing costs.

Clinically, SCIG has been shown to work well for patients transitioning from IVIG across several conditions, including primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy.⁷ The weekly dose of SCIG is calculated to match the equivalent monthly IVIG dose, so the total amount of immunoglobulin remains the same. Many patients actually prefer SCIG because the smaller, more frequent doses produce more stable immunoglobulin levels and fewer of the systemic side effects (headache, fatigue, nausea) that can follow a large monthly IVIG infusion.

If your insurer has denied IVIG, asking your physician about SCIG as an alternative can be both a clinical and an insurance strategy. Some insurers that resist IVIG authorization will approve SCIG more readily because the overall cost profile is lower. This isn’t always the right move medically, since some conditions or dosing requirements are better suited to IV administration, but it’s a conversation worth having when you’re running into coverage barriers.

What to Do While You Wait

IVIG denials and appeals can stretch out for months, and for patients with progressive or symptomatic conditions, delay itself is harmful. Several options can bridge the gap:

Expedited or urgent appeals: If your condition is deteriorating or delay poses a serious health risk, your physician can request an expedited appeal. Insurers are required to respond to urgent appeals within 72 hours for most plan types.
Manufacturer assistance programs: Some IVIG manufacturers offer patient assistance programs that provide product at reduced cost or free while insurance issues are being resolved. Your specialty pharmacy or infusion provider may know which programs are currently accepting patients.
Hospital financial assistance: If you’re being treated at a hospital-based infusion center, the hospital may have a charity care or financial assistance program that can cover or reduce your out-of-pocket costs during the appeal.
Continuation of benefits: If you were previously receiving IVIG and your insurer is denying reauthorization, some state laws and plan rules require the insurer to continue coverage at the previously approved level while the appeal is pending. Ask about this specifically, because many patients don’t realize this protection exists.

Documenting your clinical status during any treatment delay is also important for the appeal. If your symptoms worsen, your lab values deteriorate, or you experience complications while waiting for coverage, this information strengthens your case and can be added to the appeal file. Ask your physician to keep detailed notes during this period.

Dosing Disputes and Reauthorization Challenges

Even after initial approval, IVIG coverage disputes don’t necessarily end. Reauthorization is a recurring hurdle. As noted in the coverage policy review, average reauthorization periods for neuromuscular disease therapies were about ten months, meaning you face a new approval cycle roughly once a year.³ Some insurers require proof that IVIG is still necessary, which could mean updated labs, clinical assessments, or evidence that you’ve attempted to taper the dose.

Dosing itself can become a point of contention. IVIG dosing depends on the condition being treated and your body weight, and some insurers apply their own dosing guidelines that may differ from what your physician prescribes. For patients with higher body weight, there’s clinical discussion about whether dosing should be based on actual weight or adjusted weight, which can affect the total amount approved.⁸ If your insurer approves a lower dose than your physician ordered, a letter explaining the clinical rationale for the specific dose, including why a lower amount would be inadequate, can address the discrepancy.

Keep a personal file of every authorization, denial, appeal, lab result, and clinical note related to your IVIG treatment. When reauthorization comes around, having a ready-made package of documentation saves time and reduces the risk of gaps in treatment. Some patients find it useful to maintain a simple timeline showing dates of treatment, clinical responses, and any periods of interruption along with their consequences.

When an Attorney or Patient Advocate Might Help

Most IVIG coverage disputes are resolved through the standard appeal and external review process. But if you’ve exhausted all levels of appeal and external review, and you believe the denial is improper, you have additional options. Health insurance attorneys specialize in coverage disputes and can evaluate whether your insurer violated plan terms, state insurance regulations, or federal law. Many offer free initial consultations.

Patient advocates, whether independent professionals or staff at patient advocacy organizations, can help at any stage of the process. They know the language insurers respond to, they understand the specific clinical literature for various conditions, and they can help your physician craft a more effective appeal. For complex or unusual diagnoses where IVIG use is less established, having someone experienced in insurance navigation can make a real difference in the outcome. Several disease-specific nonprofits maintain lists of advocates familiar with IVIG coverage issues, and some offer advocacy services at no cost to patients.